Role of Nitric Oxide in the Control of Cardiac Oxygen Consumption in B2-Kinin Receptor Knockout Mice

Hypertension

Volumn 34, Issue 4, 1999, Pages 563-567

  Loke, Kit E ^a   Curran, Christine M L ^a   Messina, Eric J ^a   Laycock, Sarra K ^a   Shesely, Edward G ^a   Carretero, Oscar A ^a   Hintze, Thomas H ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Amlodipine; Angiotensin converting enzyme inhibitors; Heart; Oxygen

Indexed keywords

AMLODIPINE; BRADYKININ; BRADYKININ B2 RECEPTOR; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; RAMIPRILAT; SUBSTANCE P;

ANIMAL TISSUE; ARTICLE; DRUG ACTIVITY; FEMALE; HEART MUSCLE OXYGEN CONSUMPTION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; REGULATORY MECHANISM;

AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRADYKININ; CALCIUM CHANNEL BLOCKERS; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HEART; MICE; MICE, KNOCKOUT; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; OXYGEN CONSUMPTION; RAMIPRIL; RECEPTORS, BRADYKININ; SUBSTANCE P;

EID: 0032721551     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.34.4.563     Document Type: Article

References (34)

1. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
2. Vanhoutte PM, Boulanger CM, Mombouli JV. Endothelium-derived relaxing factors and converting enzyme inhibition. Am J Cardiol. 1995;76:3E-12E.
3. Dinerman JL, Lowenstein CJ, Snyder SH. Molecular mechanisms of nitric oxide regulation potential relevance to cardiovascular disease. Circ Res. 1993;73:217-222.
4. Palmer RMJ, Rees DD, Ashton DS, Moncada S. L-Arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun. 1988;153:1251-1256.
5. Shen W, Xu X, Ochoa M, Zhao G, Wolin MS, Hintze TH. Role of nitric oxide in the regulation of oxygen consumption in conscious dogs. Circ Res. 1994;75:1086-1095.
6. 2 uptake after inhibition of EDRF/NO synthesis. J Appl Physiol. 1994;76:1166-1171.
7. Xie Y-W, Shen W, Zhao G, Xu X, Wolin MS, Hintze TH. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro: implications for the development of heart failure. Circ Res. 1996;79:381-387.
8. Stadler J, Billiar TR, Curran RD, Stuehr DJ, Ochoa JB, Simmons RL. Effect of exogenous and endogenous nitric oxide on mitochondrial respiration of rat hepatocytes. Am J Physiol. 1991;260:C910-C916.
9. Borutaite V, Brown GC. Rapid reduction of nitric oxide by mitochondria, and reversible inhibition of mitochondrial respiration by nitric oxide. Biochem J. 1996;315:295-299.
10. Granger DL, Lehninger AL. Sites of inhibition of mitochondrial electron transport in macrophage-injured neoplastic cells. J Cell Biol. 1982;95:527-535.
11. Mombouli J-V, Vanhoutte PM. Kinins and endothelial control of vascular smooth muscle. Ann Rev Pharmacol Toxicol. 1995;35:679-705.
12. 2 bradykinin receptors. FASEB J. 1989;3:2019-2025.
13. Mombouli J-V, Illiano S, Nagao T, Scott-Burden T, Vanhoutte PM. Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin 1 converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors. Circ Res. 1992;71:137-144.
14. Cohn JN. ACE inhibitors in non-ischaemic heart failure: results from the MEGA trials. Eur Heart J. 1995;16(suppl):133-136.
15. Zhang X, Xie Y-W, Nasjletti A, Xu X, Wolin MS, Hintze TH. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation. 1997;95:176-182.
16. Packer M, O'Conner CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107-1114.
17. Bernstein RD, Recchia FA, Wolin MS, Hintze TH. Amlodipine regulates myocardial respiration: implications for heart failure. Circulation. 1997;96:1-571.
18. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation. 1998;97:576-580.
19. Loke KE, McConnell PI, Tuzman JM, Shesely EG, Smith CJ, Stackpole CJ, Thompson CI, Kaley G, Wolin MS, Hintze TH. Endogenous endothelial nitric oxide synthase-derived nitric oxide is a physiological regulator of myocardial oxygen consumption. Circ Res. 1999;84:840-845.
20. Umbreit WW, Burris RH, Stauffer JF. The Solubility of Oxygen: Manometric Techniques. 4th ed. Minneapolis, Minn: Burgess; 1964:5-6.
21. 2 receptor association of phospholipase Cγ1 in vascular endothelial cells. Biochem Biophys Res Commun. 1998;246:70-75.
22. Zhang X, Scicli GA, Xu X, Nasjletti A, Hintze TH. Role of endothelial kinins in control of coronary nitric oxide production. Hypertension. 1997;30:1105-1111.
23. 2-receptor gene. J Hypertens. 1997;15:1701-1706.
24. 2 bradykinin receptor gene in mice eliminates bradykinin actions in smooth muscle and neurons. J Biol Chem. 1995;270:13706-13710.
25. 2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension. 1997;30[part 2]:735-740.
26. Holdright DR, Clarke D, Fox K, Poole-Wilson PA, Collins P. The effects of intracoronary substance p and acetylcholine on coronary blood flow in patients with idiopathic dilated cardiomyopathy. Eur Heart J. 1994;15:1537-1544.
27. Diz DI, Fantz DL, Benter IF, Bosch SM. Acute depressor actions of angiotensin II in the nucleus of the solitary tract are mediated by substance p. Am J Physiol. 1997;273:R28-R34.
28. Tagawa T, Mohri M, Tagawa H, Egashira K, Shimokawa H, Kuga T, Hirooka Y, Takeshita A. Role of nitric oxide in substance p-induced vasodilation differs between the coronary and forearm circulations in humans. J Cardiovasc Pharmacol. 1997;29:546-553.
29. Krause JE, Takeda Y, Hershey AD. Structure, functions, and mechanisms of substance p receptor action. J Invest Dermatol. 1992;98:2S-7S.
30. Pernow B. Substance P. Pharmacol Rev. 1983;35:85-141.
31. Bolton TB, Clapp LH. Endothelial-dependent relaxant actions of carbachol and substance p in arterial smooth muscle. Br J Pharmacol. 1986;87:713-723.
32. Ishigai Y, Mori T, Ikeda T, Fukuzawa A, Shibano T. Role of bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardiomyocytes. Am J Physiol. 1997;273:H2659-H2663.
33. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
34. AIRE Study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.